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Abstract
A simple, selective and accurate high performance liquid chromatographic (HPLC) method was developed and validated for the
analysis of esomeprazole magnesium trihydrate (ES) in tablets. Chromatographic separation was achieved isocratically on a C18
column utilizing a mobile phase of acetonitrile/phosphate buffer (60:40, v/v, pH 7) at a flow rate of 1.0 mL/min with UV detection at
205 nm. Lansoprazole was used as an internal standard (IS). The calibration curve of ES was linear in the range of 100~1000 ng/mL
(r = 0.9992, n = 4). The RSD values for intra- and inter-day precision were 0.66~0.86% and 0.84~1.11%, respectively. The proposed
method was successfully applied to the determination of ES in tablets. The mean recovery for ES from the tablets ranged between
97.82~98.22%. ES was subjected to neutral, acid and alkali hydrolysis as well as oxidation, dry heat treatment and photodegradation.
Being simple, accurate and selective, the method can be used for routine quality control analysis.
Key words: esomeprazole, HPLC, stability-indicating, validation, tablet assay

INTRODUCTION
Different methods including UV- (3), visible- (4) and
derivative (5-7) spectrophotometry, differential scanning
calorimetry(8), HPLC(9) and capillary electrophoresis(10)
have been described for the determination of omeprazole
or its sodium salt in pharmaceutical preparations. Some
of these methods are stability-indicating(5,6,8,9). Official
methods in USP 27(11) and BP 2004(12) are based on HPLC
analysis. In biological fluids, omeprazole was mainly
determined by stereoselective HPLC techniques(13-15).
Esomeprazole magnesium trihydrate (ES), bis
(5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2pyridinyl)methyl]sulfinyl-1H-benzimidazole-1-yl)
magnesium trihydrate (Figure 1) is the S isomer of racemic
omeprazole approved in February 2001 for use as a new
pharmacological entity designed to improve the clinical
outcome of available proton pump inhibitors in the
management of acid-related disorders(1,2). Yet up to now,
there is no method available for the determination of ES.
In the present study, we developed an HPLC method
for the determination of ES in tablets. Other analytical
methods(3-10) used to quantify omeprazole in pharmaceutical
preparations are limited in terms of sensitivity and do not
have the full stability indicating properties. Hence HPLC
could be a useful tool in the analysis of the ES. Compared
to other analytical techniques described in this literature,
HPLC would afford advantages in terms of speed and
accuracy of analysis and its chromatographic run time of 4.5
min allows the analysis of a large number of samples in a
* Author for correspondence.
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short period of time. Therefore, this HPLC-UV is validated
and can be used for the rapid quantitation of ES in the
presence of its degradation products.

MATERIALS AND METHODS
I. Materials
Esomeprazole magnesium trihydrate (ES) and its
tablets (20 mg per tablet) were generous gifts from Astra
Zeneca (Istanbul, Turkey). Lansoprazole (internal standard)
was obtained from Sanovel Pharmaceutical Industries
(Istanbul, Turkey). All solvents and reagents were of
analytical or HPLC grade. HPLC-grade water was prepared
by using AquaMAX-ultra water purification system from
Young Lin Inst (Korea).
II. HPLC Instrumentation
The analyses were performed on a Thermo Separation
Products Liquid Chromatograph (TX, USA) which
consisted of a P4000 solvent delivery system equipped with
a Rheodyne injection valve with a 20-µL loop, an UV-3000
detector set at 205 nm and a SN-4000 automation system

Figure 1. Structure of esomeprazole magnesium trihydrate.
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software. Separations were carried out at room temperature
on a Phenomenex C18 column (250 × 4.6 mm I.D., 5 µm;
Therma Separation, Texas, USA), with a guard column (4
× 3 mm I.D., Phenomenex) packed with the same material.
The mobile phase consists of acetonitrile/phosphate buffer
(60:40, v/v, pH 7) at a flow rate of 1.0 mL/min. Before
used, the mobile phase was degassed by an ultrasonic bath
and filtered by a Millipore vacuum filter system equipped
with a 0.45 mm HV filter.
III. Preparation of Stock and Standard Solutions
Stock solutions of esomeprazole magnesium trihydrate
(ES) (1 mg/mL, calculated as free base) and internal
standard (1 mg/mL) were prepared in methanol and diluted
further with the mobile phase to obtain standard solutions of
10 µg/mL.
IV. Linearity
By appropriate dilution of the ES standard solution with
the mobile phase, ten working solutions ranging between
100 and 1000 ng/mL were prepared. The concentration of
IS in the samples was 800 ng/mL. The solutions (20 µL)
were injected and chromatographed (n = 4) according to
the chromatographic conditions previously given. For ES
quantitation, the chromatographic signals were evaluated on
the basis of peak area ratios of ES to IS.
V. Precision

50 and 150% of label claim were added. The mixtures were
then analyzed by the proposed method. The experiments
were conducted five times.
VIII. Robustness
Assay procedure was repeated using columns from
two different manufacturers and solvent (acetonitrile) of
two different lots. Besides, separation studies were also
performed by two different analysts.
IX. Forced Degradation of Standard ES
A stock solution prepared as 1 mg/mL ES (calculated as
base) in methanol was used for forced degradation studies.
(I) Hydrolysis
Individually, 5 mL of the standard solution was
transferred to a 10-mL distillation flask and boiled for 1 hr at
80°C after adding: (a) 5 mL of water for neutral hydrolysis
(b) 5 mL of 1 N HCl for acid hydrolysis (c) 5 mL of 1 N
NaOH for basic hydrolysis. Before the analysis, (b) and (c)
solutions were neutralized.
(II) Chemical Oxidation
To 5 mL of the standard solution, 100 µL of 30% H2O2
solution (v/v) were added and mixed. The solution was left
at room temperature for 1 hr in the dark.

The intra-day and inter-day precision were determined
by analyzing the samples of ES at concentrations of 200,
600 and 1000 ng/mL. Determinations were performed
with five replicates on the same day as well as on four
separated days.

(III) Photochemical Degradation

VI. Assay Procedure for Tablets

(IV) Thermal Stress

Twenty tablets were individually weighed to get the
average weight of the tablets. A sample of the powdered
tablets, claimed to contain 100 mg of ES was transferred
to 100-mL calibrated flask. About 75 mL of methanol was
added and then extraction was performed mechanically
for 20 min followed by sonication for 20 more min. The
volume was brought to 100 mL with methanol. The content
was centrifuged for 10 min at 3000 ×g, and then a 0.1-mL
aliquot of the supernatant was diluted to 10 mL with the
mobile phase. One milliliter of this solution and 0.8 mL of
IS standard solution were transferred into a 10-mL calibrated
flask and diluted to the volume with the mobile phase. A 20
µL of its aliquot was injected and chromatographed (n = 5).

Bulk drug was subjected to dry heat at 105°C for 5 hr.
To each of the stressed solutions, IS was added
and then it was diluted with the mobile phase to obtain
a theoretical concentration of 1000 ng/mL for ES. The
resulting concentration of IS was 800 ng/mL. Each solution
was analyzed in duplicate.

VII. Accuracy/Recovery Studies
Recovery studies were carried out with the assay
samples to which known amounts of ES corresponding to

The photochemical stability of the ES was studied by
exposing the methanolic stock solution to direct sunlight for
8 hr (from 9 AM to 5 PM at ≅ 20°C).

RESULTS AND DISCUSSION
I. Development of the HPLC Method
In order to separate ES, internal standard and
degradation products produced under stressed conditions,
aqueous buffer-acetonitrile mixtures were used as the
mobile phase. Satisfactory resolution was obtained using
the mobile phase system of acetonitrile/phosphate buffer
(60:40, v/v, pH 7) at a flow rate of 1 mL/min. As ES
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showed maximum absorption at 205 nm (Figure 2), the
detector was set at 205 nm. Under these conditions, ES was
resolved from the IS with the retention times of 3.64 ± 0.07
and 4.31 ± 0.09 min, respectively. In Figure 3, a typical
chromatogram obtained under these conditions is shown.
Chromatograms of stressed reaction solutions are given in
Figures 4 and 6. They indicate that the developed method
was successful to separate the drug and its chromophoric
degradation products.
II. Validation of the Developed Method

was found to be 10 ng/mL. The limit of quantitation was
100 ng with a coefficient of variation 1.40% (n = 4).
The intra-day (n = 5) and inter-day (n = 5, four
different days) reproducibilities expressed as relative
standard deviation (RSD) were found to be 0.66~0.86%
and 0.84~1.11%, respectively, indicating good precision
(Table 1). The relative error (R.E.) below 1.55% revealed
satisfactory accuracy for the method.
To evaluate the robustness of the method, two
analytical columns, one (Phenomenex C18 column and the

The calibration curve was prepared by plotting the
peak area ratios of ES to IS against drug concentration
and was linear in the range of 100~1000 ng/mL. The data
were subjected to least-squares linear regression analysis
to calculate the calibration equation and correlation
coefficients. The regression equation was found as
A = 0.0013C – 0.021 (r = 0.9992, n = 4) (A = aC + b where
A is the peak area ratio of ES to the IS, a is the slope, b is
the intercept and C is the concentration of the measured
solution in ng/mL). The results show that there is an
excellent correlation between the peak area ratios and the
concentrations of ES in the range tested.
The limit of detection, with a signal to noise ratio of 3:1,

Figure 2. Absorption spectrum of ES in mobile phase.
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Figure 3. (A) A typical chromatogram of 1000 ng/mL ES standard and 800 ng/mL IS, 20 mL injection, (B) UV spectrum of ES standard.

Table 1. Intra-day and inter-day precision and accuracy of ES
Intra-day (n = 5)

a

Actual concentration
(ng/mL)

Found concentration
(ng/mL)

RSD (%)

R.E.b (%)

Found concentration
(ng/mL)

RSD (%)

R.E. (%)

200
600
1000

200.31
601.54
984.46

0.80
0.66
0.86

0.16
0.26
1.55

198.77
594.11
984.99

1.11
0.84
0.95

0.61
0.98
1.50

Results of four different days.
Relative error.

b

Inter-daya (n = 5)
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other Shim-Pack CLS-ODS analytical column were used.
The assay results (mean ± RSD) found as 101.03 ± 0.67%
and 101.41 ± 1.97%, respectively, indicated that different
columns do not lead to significantly different results. Two
different lots of acetonitrile from the same manufacturer
or two different manufacturers of acetonitrile were also
tested for the robustness and only insignificant differences
in peak areas and in retention time were observed (99.62 ±

0.55% and 99.71 ± 1.23% for the two lots as well as, 98.37
± 0.41% and 98.65 ± 1.10% for the two manufacturers).
The proposed method was carried out by two analysts
and no considerable difference was observed ( 99.66 ±
0.75% vs. 99.81 ± 0.41%). The RSD values of less than
2.0% for peak areas and retention times indicated that the
developed method was capable of producing results with
high precision.
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Figure 4. Chromatograms corresponding to ES solution subjected to (A) neutral and (B) alkaline hydrolysis, (C) chemical oxidation, (D) acid
hyrolysis and (E) thermal stress.
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III. Assay Procedure for Tablets
The proposed method was applied to the analysis of
marketed product (Nexium tablet) and the results obtained
are given in Table 2. The blank solution was prepared
containing the components indicated in tablets except the
active principle. No interference was observed from the
tablet excipients.
To examine the accuracy of the method, recovery
studies were carried out by standard addition method. The
percent recovery of the added standard to the assay samples
was calculated from:
Recovery % = [(Ct – Cu) / Ca] × 100
where Ct is the total concentration of the analyte found; Cu
is the concentration of the analyte present in the formulation;
and Ca is the concentration of the pure analyte added to the
formulation. The results are shown in Table 3. The average
percent recoveries obtained as 97.82~98.22% indicate good
accuracy of the method.

When the ES solution was exposed to neutral and
basic hydrolysis, and chemical oxidation with H2O2, the
chromatographic peaks corresponding to the parent drug
reduced indicating that the compound was decomposed
about 40%, 15% and 25%, respectively (Figure 4 A~C).
The peak purity of the parent drug was checked by its
UV spectrum (Figure 5). On the other hand, after the
acidic hydrolysis, the peak corresponding to the parent
drug substantially disappeared (Figure 4 D). Degradation
products could not be distinguished because the peaks
observed with retention time between 1~3 min were also
present in the chromatograms of the blank studies. As can
be seen from Figure 4 (D), these peaks did not interfere with
the signal corresponding to the parent drug, which has a
retention time of 3.64 min.
No decomposition was observed when the ES as
powder was subjected to dry heat at 105°C for 5 hr
1.0
Neutral hydrolysis
Chemical oxidation
Thermal stress
Alkaline hydrolysis

Neutral
hydrolysis

→

Stability-indicating methods have received
considerable attention for the determination of a vast
number of drugs(16-20). The International Conference on
Harmonization (ICH) guideline entitled “Stability Testing
of New Drug Substances and Products” requires the stress
testing to be carried out to elucidate the inherent stability
characteristics of the active substances(21). Susceptibility
to oxidation is one of the required tests. The hydrolytic and
photolytic stabilities are also required. An ideal stabilityindicating method is one that quantifies the drug per se and
also resolves its degradation products.
In order to check the proposed method for selectivity,
different degradation pathways for ES were performed, due
to that its degradation products were not available. This
study was carried out by employing the following tests:
hydrolysis (neutral, acidic and basic), chemical oxidation,
photolysis and thermolysis.

→

IV. Selectivity

0.0

Chemical
oxidation
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Figure 5. The UV spectrum of the chromatographic peak
corresponding to the parent drug after subjected to neutral, alkaline
hydrolysis, chemical oxidation and thermal stress.

Table 2. Analysis of ES in tablets
Formulation

Label claim
(mg/per tablet)

Amount found ± S.D.b
(mg, n = 5)

Recovery (%)

RSD (%)

Nexiuma

20

19.81 ± 0.17

99.05

0.86

a

Marketed by Astra Zeneca.
Standard deviation.

b

Table 3. Results of recovery studies by standard addition method

a

Amount of drug
in tablet (mg)a

Amount of pure
drug added (mg)

Total found (mg)b
(mean ± S.D.c)

RSD (%)

Recovery of pure
drug added (%)

19.81

10

29.63 ± 0.3

1.02

98.22

19.81

50

68.72 ± 0.6

0.92

97.82

Nexium tablet (20 mg).
Five independent analyses.
c
Standard deviation
b
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Figure 6. (A) Chromatogram of ES exposed to sunlight for 8 hr, (B) UV spectrum of the degradation product 1 (Rt = 1.98).

Table 4. Degradation trial for ES

1200

Concentration (ng/mL)

1000
800
600
400

Condition
Acid, 1 N HCl, 80°C
Base, 1 N NaOH, 80°C

Time (hr)
1
1

Recovery (%)
Not detected
85.08

Neutral hydrolysis, 80°C

1

58.42

H2O2, 30%, at room temperature

1

74.23

Dry heat 105°C
Daylight 20°C

5
8

99.42
Not detected

200
0

0

100

200

300
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Figure 7. Effect of sunlight on the concentration of ES during 8
exposure.

indicating that heating had no effect on the ES (Figure 4 E ).
When the ES solution was exposed to the sunlight,
almost complete degradation of the drug was observed and
a new signal appeared in the chromatogram. As can be seen
from Figure 6, resolution of ES from its photodegradation
product could be achieved. Effect of sunlight on the
concentration of ES during 8 hr is shown in Figure 7. This
test showed that ES in methanol solution is very sensitive to
sunlight exposure.
Recovery data of the degradation tests for ES are given
in Table 4.
In conclusion, forced degradation studies under
described conditions showed that ES solution remained
stable under thermal stress but degraded partially with
neutral and basic hydrolysis, and chemical oxidation, and
totally, with acid hydrolysis and exposure to sunlight.

These results are in accordance with the ones obtained with
omeprazole and omeprazole sodium(8,9). The proposed
method can be used as a stability-indicating one because
the peak of the parent drug, ES, is not interfered by any
other signal in the chromatogram. The method has one
disadvantage of not being stereo-selective.

CONCLUSIONS
This is the first report to describe a simple and stabilityindicating HPLC method for the analysis of esomeprazole
magnesium trihydrate in tablets. Acquired validation
parameters indicate that the proposed method is selective,
precise, accurate, robust and hence suitable for routine
analysis of ES in tablets.
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